Table 1 Basic characteristics of all patients
From: Effects of metformin therapy on HMGB1 levels in rheumatoid arthritis patients
Variable | Metformin group, n = 124 | Conventional therapy group, n = 98 | p |
|---|---|---|---|
Age, y | 51.5 (38–65) | 52 (31–69) | 0.492 |
Sex, female (%) | 91 (73.39) | 71 (72.45) | 0.999 |
BMI | 25.39 ± 2.22 | 25.22 ± 2.24 | 0.577 |
course of disease, y | 4 (1–9) | 5 (1–10) | 0.345 |
ESR (mm/h) | 29.01 ± 16.24 | 26.82 ± 15.78 | 0.312 |
RF (IU/ml) | 160.03 ± 107.40 | 160.71 ± 108.26 | 0.983 |
VAS score | 3.9 (0.7–5.8) | 4.1 (0.8–5.7) | 0.878 |
CRP (pg/ml) | 127.08 ± 26.43 | 128.29 ± 27.27 | 0.738 |
IL-6 (pg/ml) | 32.82 ± 9.93 | 33.39 ± 10.31 | 0.675 |
TNF-α (pg/ml) | 53.21 ± 5.36 | 53.83 ± 5.03 | 0.382 |
HMGB1 (pg/ml) | 85.49 ± 16.34 | 84.56 ± 14.56 | 0.662 |
DAS-28 score | 3.02 (0.74–5.53) | 3.08 (0.70–5.45) | 0.901 |